BB - The amount of intellectual spoon-feeding needed for some is quite something. As I posted yesterday. Roswell rounds out the repertoire of DC based modalities to solidify NWBO'S bases for being a platform. The move also removes any potential weakness potentially, that a suiter may have had concerns with, or tried to use, as a sticking point to leverage in negotiations. Also, what biotech company wouldn't love trials run on someone else's time? It's bizarre not to see that as a glaring home run. Absolutely, trials run upwards of a $billion plus through phases 1 thru 3. All these milestones continue to build huge value, which any suiter, or potential Partner would be paying for. "There's no free ride as they say."
Market Data 
Markets 
